Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement (TAVI). Some recent data finally condensed in the present meta-analysis and recently published in JAHA happen to challenge these guidelines. 

duración terapia de doble antiagregación plaquetaria

Clinical studies that investigated single antiplatelet therapy versus DAPT until November 2020 were analyzed and divided according to DAPT duration. 

Researchers calculated risk ratios of major or life‐threatening bleeding, stroke, and all‐cause mortality. 

Studies using oral anticoagulants and antiplatelet therapy concomitantly, such as those on atrial fibrillation, were excluded. 

It included four randomized controlled trials, 2 propensity‐score matched studies, and 1 observational study, with a total 2498 patients.

1249 received monotherapy, 485 received DAPT for 3 months and 764 received DAPT for 6 months. All these studies used aspirin as monotherapy. 


Read also: CT and Angiography Agreement in Patients from the ISCHEMIA Trial.


The analysis showed that aspirin monotherapy significantly reduced the risk of life-threatening bleeding vs. 3-month DAPT (RR=2.13, p=0.016) and 6-month DAPT (RR=2.54, p=0.007).

There were no differences when comparing 3-month vs 6-month DAPT.

Stroke and mortality rates were similar across groups. 


Read also: Cerebral Protection Devices during TAVR in the Daily Practice.


Clinical guidelines indicating post TAVR DAPT await updating after several studies, and more recently, a meta-analysis with consistent results in favor of monotherapy. 

Conclusion

Aspirin monotherapy after TAVR reduced the risk of bleeding and did not increase stroke or mortality rate vs. 3- and 6-month DAPT. 

JAHA-120-019490free

Original Title: Duration of Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement: Systematic Review and Network Meta-Analysis.

Reference: Toshiki Kuno et al. J Am Heart Assoc. 2021;10:e019490.  DOI: 10.1161/JAHA.120.019490.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...

TAVI and Hypertrophic Cardiomyopathy: An Increasingly Common Association

Stenosis is a common disease affecting 5% of the elderly population. It is associated with hospitalizations, poor quality of life, and mortality.  The association between...

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...